Levosimendan No Home Run in ADHF Studies : Some cite lethality as a reason to consider using the drug; whereas others point to concerns about safety.

Dr. Packer is a consultant to Abbott Laboratories and Orion Pharma, which funded REVIVE II and SURVIVE. Dr. Mebazaa is a consultant to Abbott.

70563_fx1.sml

Intravenous diuretics will remain the initial intervention for patients who present with ADHF. DR. PACKER